Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Hyperlipoproteinemias

Free Subscription Articles published in Circulation Retrieve available abstracts of 23 articles: HTML format

Single Articles

April 2024
1. TAMARGO IA, Baek KI, Xu C, Kang DW, et al
   HEG1 Protects Against Atherosclerosis by Regulating Stable Flow-Induced KLF2/4 Expression in Endothelial Cells.
   Circulation. 2024;149:1183-1201.
   PubMed     Abstract available
   
   
   February 2024
2. STONE NJ, Blum C
   If Action is Delayed, Is Survival Denied? Management of Severe Hypercholesterolemia Is Important and Urgent.
   Circulation. 2024;149:427-429.
   PubMed    
   
   
   January 2024
3. SANTOS RD, Cuchel M
   LDL-C-Lowering Therapies for Adults and Children With Homozygous Familial Hypercholesterolemia: Challenges and Successes.
   Circulation. 2024;149:363-366.
   PubMed    
   
   
   November 2023
4. YALCINKAYA M, Liu W, Thomas LA, Olszewska M, et al
   BRCC3-Mediated NLRP3 Deubiquitylation Promotes Inflammasome Activation and Atherosclerosis in Tet2 Clonal Hematopoiesis.
   Circulation. 2023;148:1764-1777.
   PubMed     Abstract available
   
   
   
5. MILES J, Scotti A, Castagna F, Kuno T, et al
   Long-Term Mortality in Patients With Severe Hypercholesterolemia Phenotype From a Racial and Ethnically Diverse US Cohort.
   Circulation. 2023 Nov 16. doi: 10.1161/CIRCULATIONAHA.123.064566.
   PubMed     Abstract available
   
   
   October 2023
6. WIEGMAN A, Greber-Platzer S, Ali S, Doortje Reijman M, et al
   Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia.
   Circulation. 2023 Oct 20. doi: 10.1161/CIRCULATIONAHA.123.065529.
   PubMed     Abstract available
   
   
   
7. RAAL F, Durst R, Bi R, Talloczy Z, et al
   Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial.
   Circulation. 2023 Oct 18. doi: 10.1161/CIRCULATIONAHA.122.063460.
   PubMed     Abstract available
   
   
   September 2023
8. ALDANA-BITAR J, Karlsberg RP, Budoff MJ
   Letter by Aldana-Bitar et al Regarding Article, "Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients With Familial Hypercholesterolemia: The ARCHITECT Study".
   Circulation. 2023;148:1057.
   PubMed    
   
   
   
9. PEREZ DE ISLA L, Saltijeral Cerezo A, Mata P
   Response by Perez de Isla et al to Letter Regarding Article, "Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients With Familial Hypercholesterolemia: The ARCHITECT Study".
   Circulation. 2023;148:1059-1060.
   PubMed    
   
   
   
10. LONG X, Jiang M
    Letter by Long and Jiang Regarding Article, "Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients With Familial Hypercholesterolemia: The ARCHITECT Study".
    Circulation. 2023;148:1058.
    PubMed    
    
    
    July 2023
11. JOHNS DG, Campeau LC, Banka P, Bautmans A, et al
    Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor.
    Circulation. 2023;148:144-158.
    PubMed     Abstract available
    
    
    May 2023
12. ZHANG Y, Dron JS, Bellows BK, Khera AV, et al
    Association of Severe Hypercholesterolemia and Familial Hypercholesterolemia Genotype With Risk of Coronary Heart Disease.
    Circulation. 2023;147:1556-1559.
    PubMed    
    
    
    April 2023
13. PEREZ DE ISLA L, Diaz-Diaz JL, Romero MJ, Muniz-Grijalvo O, et al
    Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study.
    Circulation. 2023 Apr 3. doi: 10.1161/CIRCULATIONAHA.122.062557.
    PubMed     Abstract available
    
    
    February 2023
14. PAN C, Herrero-Fernandez B, Borja Almarcha C, Gomez Bris R, et al
    Time-Restricted Feeding Enhances Early Atherosclerosis in Hypercholesterolemic Mice.
    Circulation. 2023;147:774-777.
    PubMed    
    
    
    October 2022
15. SHOTWELL MK, Vorla M, Kalra DK
    Very High Cholesterol Mimicking Homozygous Familial Hypercholesterolemia.
    Circulation. 2022;146:1182-1188.
    PubMed    
    
    
    August 2022
16. RIDKER PM, Rifai N, MacFadyen J, Glynn RJ, et al
    Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1beta, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholi
    Circulation. 2022;146:372-379.
    PubMed     Abstract available
    
    
    May 2022
17. BERGMARK BA, Marston NA, Bramson CR, Curto M, et al
    Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70.
    Circulation. 2022;145:1377-1386.
    PubMed     Abstract available
    
    
    February 2022
18. SEMOVA I, Levenson AE, Krawczyk J, Bullock K, et al
    Insulin Prevents Hypercholesterolemia by Suppressing 12a-Hydroxylated Bile Acid Production.
    Circulation. 2022 Feb 23. doi: 10.1161/CIRCULATIONAHA.120.045373.
    PubMed     Abstract available
    
    
    June 2021
19. KUEHN BM
    Evinacumab Approval Adds a New Option for Homozygous Familial Hypercholesterolemia With a Hefty Price Tag.
    Circulation. 2021;143:2494-2496.
    PubMed    
    
    
    March 2021
20. 
    Correction to: Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia.
    Circulation. 2021;143:e799.
    PubMed    
    
    
    November 2020
21. KULLO IJ
    Familial Hypercholesterolemia: A Reportable Disorder.
    Circulation. 2020;142:1999-2001.
    PubMed    
    
    
    October 2020
22. MSZAR R, Nasir K, Santos RD
    Coronary Artery Calcification in Familial Hypercholesterolemia: An Opportunity for Risk Assessment and Shared Decision Making With the Power of Zero?
    Circulation. 2020;142:1405-1407.
    PubMed    
    
    
    November 2019
23. DAMASK A, Steg PG, Schwartz GG, Szarek M, et al
    Patients with High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit from Alirocumab Treatment in the Odyssey Outcomes Trial.
    Circulation. 2019 Nov 11. doi: 10.1161/CIRCULATIONAHA.119.044434.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hyperlipoproteinemias is free of charge.